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ABSTRACT
Background
Cryptococcosis is a life-threatening opportunistic fungal infection in both HIV-positive
and -negative patients. Information on clinical presentation and therapeutic guidelines, derived
mostly from clinical trials performed before introduction of highly active antiretroviral therapy
in patients with cryptococcal meningoencephalitis, is missing data on extrameningeal
involvement and infections by serotype D as opposed to serotype A of Cryptococcus
neoformans.
Methods and Findings
The prospective multicenter study CryptoA/D was designed in France (1997–2001) to analyse
the factors influencing clinical presentation and outcome without the bias of inclusion into
therapeutic trials. Of the 230 patients enrolled, 177 (77%) were HIV-positive, 50 (22%) were
female, and 161 (72.5%) were infected with serotype A. Based on culture results at baseline,
cryptococcosis was more severe in men, in HIV-positive patients, and in patients infected with
serotype A. Factors independently associated with mycological failure at week 2 independent
of HIV status were initial dissemination (OR, 2.4 [95% confidence interval (CI), 1.2–4.9]), high
(.1:512) serum antigen titre (OR, 2.6 [1.3–5.4]), and lack of flucytosine during induction therapy
(OR, 3.8 [1.9–7.8]). The three-month survival was shorter in patients with abnormal neurology or
brain imaging at baseline, and in those with haematological malignancy.
Conclusions
Thus sex, HIV status, and infecting serotype are major determinants of presentation and
outcome during cryptococcosis. We propose a modification of current guidelines for the initial
management of cryptococcosis based on systematic fungal burden evaluation.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Cryptococcosis is a deadly opportunistic infection caused
by an encapsulated yeast, Cryptococcocus neoformans. The major
predisposing factor is the profound cellular immune defect
caused by HIV infection, but other T cell–related immune
defects and immunosuppressive treatments can also be
associated [1]. Despite major advances in the treatment of
HIV infection with highly active antiretroviral therapy
(HAART), cryptococcosis is still diagnosed in Western
countries [2–4]. In the southern part of Africa and in
Southeast Asia, cryptococcosis remains a major concern, with
up to 30% of AIDS patients presenting with C. neoformans
infections [5,6].
C. neoformans variety grubii (serotype A) [7] has a worldwide
distribution and is often described as the unique serotype
causing infection in HIV-positive patients [8,9]. In Europe,
however, variety neoformans (serotype D) is also responsible for
infections in almost 20% of HIV-positive patients [10,11].
Variety gattii (serotypes B and C), recently raised to species
level as Cryptococcus gattii [12], is usually limited to tropical and
subtropical areas [13,14]. Several studies have shown that
serotypes A and B differ in terms of host infected, geographic
distribution, presentation of disease, outcome, and therapeu-
tic management [15–17]. Variety grubii and variety neoformans
were found to differ in terms of host infected and disease
pattern in a retrospective analysis [10], although this ﬁnding
will need conﬁrmation in a prospective study.
Several prospective randomized therapeutic trials per-
formed before the HAART era have been used to develop
therapeutic guidelines for the management of HIV-positive
patients with cryptococcosis [18]. With the contribution of
earlier trials, guidelines were subsequently extrapolated for
HIV-negative patients [19]. Description of disease presenta-
tion and outcome as well as factors inﬂuencing sterilisation of
cerebrospinal ﬂuid (CSF) or therapeutic failure have been
published in HIV-negative [19–21] and -positive populations
[22–24], mostly after analysis of therapeutic trials conducted
in countries where variety neoformans (serotype D) is rarely
recovered. Moreover, exclusion criteria for therapeutic trials
usually reject the most severely affected patients and those
without meningitis. Finally, with the exception of one recent
study, which showed that male sex is an independent factor
for mortality in HIV-negative patients with cryptococcal
meningoencephalitis [21], no study so far has looked for the
potential impact of host factors such as sex or HIV status, or
of infecting variety grubii versus neoformans on clinical
presentation, therapeutic management, and outcome of
infection.
A nationwide multicenter prospective study (the CryptoA/
D study) was thus designed in France in 1997—i.e. in the
HAART era—to address two questions: First, what are the
factors inﬂuencing clinical presentation and outcome in
HIV-positive and -negative patients with cryptococcosis? And
second, do infections by C. neoformans variety grubii and
neoformans differ in these respects?
Methods
Study Design
The nationwide multicenter prospective study was imple-
mented by the National Reference Center for Mycoses
(NRCM, Institut Pasteur, France) between 1 April, 1997 and
1 July, 2001. The study was approved by the local ethical
committee and reported to the French Ministry of Health
(registration # DGS970089). All adults (i.e.,   18 years of age),
whether HIV infected or not, experiencing a ﬁrst episode of
culture-proven cryptococcosis, were eligible. Culture of
blood, CSF, and urine were performed when the ﬁrst
evidence of cryptococcosis was found (i.e., positive culture
from any body site, positive cryptococcal antigen testing,
presence of encapsulated yeasts). Two weeks (Wk2) and three
months (Mo3) after antifungal therapy was started, culture of
initially infected body sites (i.e., those with positive culture)
was requested. Patients’ management regarding other inves-
tigations and therapeutic decisions was left to the physician
in charge. Likewise, laboratory choices (cryptococcal antigen
detection kit, medium, or duration of culture incubation)
followed local practices.
A 16-page questionnaire (Text S1) was mailed upon receipt
of the signed informed consent and anonymity was preserved.
The information collected concerned epidemiological, clin-
ical, biological, radiological, and mycological data at the time
of antifungal therapy initiation (D0, baseline) as well as
clinical and mycological status, treatment, and follow-up at
Wk2 and Mo3. Any missing information or ambiguous answer
was checked by phone with the physician or biologist in
charge, and/or by careful review of the chart by at least one of
us. All infecting isolates were collected and sent to the NRCM
for serotyping [25].
Definitions
A case was deﬁned by isolation of C. neoformans from at least
one body site. Classiﬁcation of HIV-positive patients was
based on the standard criteria established by the US Centers
for Disease Control and Prevention in 1993 [26]. For each
patient, extrapulmonary cryptococcosis was considered an
AIDS-deﬁning illness (sometimes revealing HIV infection) or
not depending on the stage of HIV infection. Patients were
classiﬁed according to their continent of birth (Europe,
Africa, or others). Cases were classiﬁed as cryptococcal
meningoencephalitis (assessed by C. neoformans-positive CSF
culture, positive direct examination, and/or antigen testing
[27]) or as extrameningeal cryptococcosis. Dissemination
required that at least two noncontiguous body sites were
infected. Abnormal neurology was deﬁned by presence of
seizures, abnormal mental status, and/or neurological defect
[22,28,29]. Results of brain or thoracic imaging were reported
by the clinician as normal or abnormal after local evaluation
but without further description of the lesions. Initial therapy
was recorded (systemic antifungal regimen administered for
at least two consecutive days). Induction therapy deﬁned the
regimen that was used for at least ﬁve days during the acute
phase of the disease, i.e., between baseline and the Wk2
evaluation. Clinical failure consisted of exacerbation of
symptoms or death before evaluation, whereas clinical cure
was deﬁned by disappearance of all initial clinical abnormal-
ities. Mycological outcome was evaluated only in patients for
whom at least one body site was sampled at the time of
workup (Wk2 or Mo3). Mycological failure meant that at least
one of the cultured samples contained viable C. neoformans;
mycological cure was deﬁned as negative cultures for initially
infected sites.
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Cryptococcosis in AdultsStatistical Analysis
Means and standard deviations (SDs) are shown when
distributions were conﬁrmed normal; medians and inter-
quartile ranges (IQRs) are reported otherwise. We compared
baseline characteristics of groups by the v
2 test or Fisher
exact test for categorical variables, and the t-test for
continuous variables. Our principal outcomes were myco-
logical failure at Wk2 and overall survival at Mo3. Thus, a
difference was considered to be statistically signiﬁcant after
Bonferroni adjustment at p , 0.001 [30]. Other comparisons
were exploratory analyses and we did not adjust the p-value.
For the multivariate analysis, we used logistic regression to
determine factors associated with mycological failure at Wk2
in the total population, and to explain the lack of CSF
sterilisation at Wk2 in HIV-positive patient with cryptococcal
meningitis. Odds ratios (ORs) and their 95% conﬁdence
intervals (95% CIs) were determined by means of logistic
regression analysis. Variables that were clinically relevant
with p , 0.25 were entered simultaneously into the initial
model. Variables were removed following a backward-step-
wise selection procedure, leaving only variables with p , 0.05
in the ﬁnal model. Moreover, interaction terms were ex-
plored on the basis of our ﬁnal model. All variables retained
were also tested by adding covariables (product of two
variables) in the ﬁnal logistic model. The statistical signiﬁ-
cance of interaction term was determined by p-value from the
logistic regression.
Early deaths (before Wk2) were described and compared to
latedeaths(mortalityrate).Finally,weanalysedoverallsurvival
at Mo3. We estimated overall survival (cumulative survival
probabilities and their 95% CIs) by the Kaplan-Meier method,
andcomparisonsofsurvivalbetweengroupswasperformedby
log-rank tests. Overall survival was measured from the date of
diagnosis to the last follow-up or death from any cause.
Each variable had a code corresponding to the absence of
information. Thus, the analysis took into account only cases
for which the corresponding parameter was available (lacking
information was coded as missing value; Figure 1 shows the
sample population at each study point). All variables were
coded and analysed with Stata software v. 8.2 (Stata Statistical
Software, http://www.stata.com).
Results
Demographic Characteristics of the Study Population
Over the 48 mo of study, 230 patients were enrolled in 77
medical centres throughout France, corresponding to 57% of
the total number of cases reported to the ongoing nationwide
surveillance program [31]. Heavier work load for the staff
taking care of the patient and refusal to sign the consent
accounted for most reasons of nonentry. There was no
difference in the inclusion rate according to the year of study,
the patient’s gender or HIV status, or the presence of CSF,
blood, urine, or skin involvement (Table S1).
The majority (142 [62%]) of the patients were HIV infected
and male. Characteristics differed signiﬁcantly between HIV-
positive and -negative patients, with a higher proportion of
patients born in Africa (59 [33.5%] versus 7 [3%], p ¼ 0.005)
and living in the Paris area (112 [63%] versus 21 [40%], p ¼
0.003), and a smaller proportion of patients in frequent
contact with bird droppings (21/160 [13%] versus 16/48 [33%],
p ¼ 0.002) in HIV-positive compared to HIV-negative
patients. Of note, more than half of the HIV-positive (57%)
and -negative (51%) patients were or had been smokers.
HIV-positive patients. Among the 177 HIV-positive pa-
tients, females were signiﬁcantly younger (mean age in years
6 SD: 36.3 6 9.8 versus 39.9 6 8.0, p ¼ 0.027) and more
frequently born in Africa (23 [66%] versus 36 [26%], p ,
0.001) than males. There was no difference between male and
Figure 1. Number of Patients Alive, Assessable, and Dead at Each Study Point
Data are from the French prospective multicentre CryptoA/D study. Pts, patients.
doi:10.1371/journal.pmed.0040021.g001
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Cryptococcosis in Adultsfemale patients in the percentage of cryptococcosis deﬁning
AIDS (65%) including those revealing HIV infection (55%),
diagnosed simultaneously with another opportunistic infec-
tion. CD4
þ T lymphocytes cell counts/ll (mean 6 SD¼45.1 6
65.8), viral load (log10 copies/ml) (4.9 6 1.0), and the
proportion of patients treated by antiretroviral drugs at
baseline (40%) were similar among genders (Table S2). In
addition to the cellular immune defect related to HIV
infection, other potentially predisposing conditions were
found: pregnancy (two patients), infections with hepatitis B
and C viruses (three and two patients, respectively) [32]. One
patient was infected with HIV type 2.
HIV-negative patients. Among the 53 HIV-negative pa-
tients, four groups were deﬁned: group 1, solid organ
transplantation (11 patients); group 2, malignancies (21
patients); group 3, various underlying disorders or treatments
(12 patients); and group 4, no identiﬁed risk factors (nine
patients). Transplanted organs were kidneys (eight cases),
liver (two cases), and heart (one case). Among the patients
with malignancies, three had solid tumours and 19 had
haematological malignancies (seven lymphomas and 12
lymphoid leukaemias). In groups 1 and 2, additional potential
risk factors were identiﬁed in 15 patients (diabetes mellitus,
chronic renal failure, tuberculosis, hepatitis B virus-related
cirrhosis, chronic hepatitis C). In group 3, risk factors
associated with potential or demonstrated immunosuppres-
sion were those described in other studies (diabetes mellitus,
cirrhosis, sarcoidosis, idiopathic CD4
þ T lymphocytopenia,
hypogammaglobulinaemia, corticosteroid therapy) [20,21,28].
Among the nine patients without any identiﬁed risk factors,
ﬁve had experienced a recent injury evoking primary
cutaneous cryptococcosis [33]. Recent (,3 mo) or current
immunosuppressive regimens including corticosteroids were
prescribed to 62% of all patients (none in group 4).
Baseline Clinical and Radiological Characteristics of
Patients with Incident Cryptococcosis
Baseline clinical characteristics and ﬁrst symptoms of
cryptococcosis differed according to HIV status (Tables 1
and S3). Intracranial pressure was not monitored routinely.
Overall, the ﬁrst notiﬁed symptom was in order of frequency:
headache (75 [34%]), fever (50 [23%]), abnormal mental
status, skin lesions, and cough (19–20 each [9%]). Mean time
between onset of symptoms and hospitalisation was signiﬁ-
cantly longer for HIV-negative than HIV-positive patients
with meningoencephalitis (mean 6 SD in weeks, 6.0 6 7.4
versus 3.3 6 3.3, p ¼ 0.0019).
Abnormal neurology (abnormal mental status [62 (33%)],
motor or cranial nerves palsies [29 (15%)], seizures [18
(10%)]) was observed in almost half (86 [46%]) of patients
with cryptococcal meningoencephalitis without a difference
according to HIV status. Abnormal thoracic images were
more frequent among HIV-negative patients, but nonre-
corded unrelated conditions could account for these chest X-
ray abnormalities, preventing further analysis.
Table 1. Baseline Clinical, Radiological, and Mycological Characteristics in 230 Adult Patients with Culture-Confirmed Cryptococcosis
According to HIV Serostatus
Category Parameter HIV-Positive
Patients (n ¼ 177)
HIV-Negative
Patients (n ¼ 53)
p-Value
Clinical parameters at baseline Sex ratio, M:F 4:1 2.5:1 0.189
Mean age in years 6 SD (examined) 39.2 6 8.4 (177) 53.9 6 17.4 (53) ,0.001
Mean body mass index 6 SD (examined) 20.0 6 3.1 (155) 21.3 6 4.1 (42) 0.02
Body temperature .38 8C, % (positive/examined) 70.1 (124/177) 54.7 (29/53) 0.047
Meningism, % (positive/examined) 68.4 (121/177) 37.7 (20/53) ,0.001
Abnormal neurology
a, % (positive/examined) 39.6 (70/177) 37.8 (20/53) 0.873
Radiology Abnormal brain imaging, % (positive/examined) 31.1 (47/151) 22.2 (8/36) 0.318
Abnormal chest X-ray or CT scan, % (positive/examined) 39.3 (68/173) 55.1 (27/49) 0.052
Mycological results Positive blood culture, % (positive/examined) 46.4 (78/168) 11.8 (8/51) ,0.001
Positive CSF culture, % (positive/examined) 88.6 (156/176) 69 (29/42) 0.003
Positive urine culture, % (positive/examined) 30.5 (47/154) 25 (13/52) 0.486
Disseminated infection, % (positive/examined) 60.6 (103/170) 38.5 (20/52) 0.007
Serotype A isolate, % (positive/examined) 76 (130/171) 60.8 (31/51) 0.048
Serum antigen detection, % (positive/examined) 95.2 (158/166) 74.5 (38/51) ,0.001
Serum antigen detection in patients with disseminated
cryptococcosis, % (positive/examined)
100 (96/96) 84.2 (16/19) 0.004
Serum antigen detection in patients with meningoencephalitis,
% (positive/examined)
97.3 (142/146) 86.2 (25/29) 0.027
Mean serum antigen titer, log2 6 SD 9.2 6 0.4 (158) 6.1 6 0.6 (38) ,0.001
CSF characteristics in patients
with meningoencephalitis
b
Positive India ink, % (positive/examined) 87.8 (137/156) 51.6 (16/31) ,0.001
Median CSF cell count/ll (IQR) (examined) 16 (3–75) (153) 82 (19–160) (29) 0.027
Median CSF protein, g/l (IQR) (examined) 0.7 (0.4–1.2) (152) 0.9 (0.7–1.2) (31) 0.035
Mean CSF:serum glucose ratio 6 SD (examined) 0.46 6 0.21 (141) 0.35 6 0.24 (26) 0.04
Positive CSF antigen, % (positive/examined) 97.2 (137/141) 100 (29/29) 1
Mean CSF antigen titer, log2 6 SD (examined) 8.3 6 0.3 (137) 6.2 6 0.9 (29) 0.019
aDefined by abnormal mental status, seizures, neurological defects.
bBased on positive culture or, in case of negative culture, a positive examination or a positive antigen determination.
doi:10.1371/journal.pmed.0040021.t001
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Cryptococcosis in AdultsBaseline Mycological and CSF Characteristics of Patients
with Incident Cryptococcosis
At least two body sites were cultured in 222 [97%] of the
patients. Cryptococcal meningoencephalitis was mostly diag-
nosed by culture except in one HIV-positive patient (positive
antigen) and two HIV-negative patients (one positive antigen
and one positive India ink).
CSF characteristics differed between HIV-positive
and -negative patients with meningoencephalitis (Tables 1
and S3). Four HIV-positive patients with positive CSF culture,
including two with positive India ink test, had negative
antigen detection in CSF. Three of the 19 HIV-negative
patients with disseminated cryptococcosis and two of six
HIV-negative patients with fungaemia had negative serum
antigen detection compared to none of the HIV-positive
patients in the same situation (n ¼ 96 and 74, p ¼ 0.028 and
0.005, respectively). Among patients with extrameningeal
cryptococcosis, 20% had negative antigen detection without a
difference according to HIV status. Finally, a discrepancy in
antigen detection between serum and CSF (negative in serum
and positive in CSF) was seen in six cases (two HIV-positive
and four HIV-negative patients, all with positive CSF culture
and only one with disseminated infection). Overall, serum
antigen titres were signiﬁcantly higher in patients with
disseminated infection or fungaemia than in those without
(p , 0.001). A threshold of antigen titer ( 1:512) was chosen
for most of the analyses, since the proportion of samples with
high antigen titres was not signiﬁcantly different according to
the commercial kit used for titration (unpublished data).
Differences of Baseline Characteristics According to Sex in
HIV-Positive Patients
Fungaemia was signiﬁcantly more frequent among male
than among female patients, as were positive urine cultures
and disseminated infections (Table 2). In patients with
meningoencephalitis, characteristics of the CSF were similar
between genders. Serum but not CSF antigen titres were
signiﬁcantly higher in males than in females. The time
interval between hospitalisation and onset of antifungal
therapy tended to be longer for female than for male
patients. The only signiﬁcant difference among HIV-negative
patients was a lower CSF antigen titre recorded in female
versus male patients (Table S4).
Differences According to the Infecting Variety/Serotype of
C. neoformans
The inﬂuence of the infecting serotype on the clinical
presentation and outcome differed in HIV-positive
and -negative patients (Table 3). Similar patterns were seen
in both populations regarding the continent of origin, the
proportion of smokers, proportion of severe hyponatraemia,
and the delay in antifungal drug prescriptions while trends
were divergent for others (serum and CSF antigen titres,
proportion of meningoencephalitis) or seen only in HIV-
negative patients (higher proportion of death from crypto-
coccosis).
Outcome Two Weeks after Onset of Antifungal Treatment
The most frequently prescribed antifungal therapy during
the induction phase was the combination of amphotericin B
and ﬂucytosine in HIV-positive patients (91/176 [52%] versus
15/53 [28%] in HIV-negative patients, p ¼ 0.003) while the
majority (31/53 [58%]) of HIV-negative patients received
monotherapy with amphotericin B or ﬂuconazole. Use of
ﬂucytosine during induction therapy was not altered by HIV
status in patients with meningoencephalitis even though it
was less frequent in HIV-seronegative patients with haemato-
logical malignancies (91/157 [58%] in HIV-positive patients;
50%–66% in groups 1 (4/8), 3 (4/7), and 4 (2/3) of HIV-
negative patients; and 4/13 [31%] in group 2; p ¼ 0.425). To
avoid the bias in daily dosage linked to prescription habits or
underlying diseases we analysed therapeutic efﬁcacy in terms
of cumulative doses (¼ daily dosage 3 duration). Mean
durations of induction therapy were not signiﬁcantly differ-
ent according to HIV serostatus (12.3 6 4.3 d versus 13.9 6
4.7 d for ﬂucytosine, p¼0.202, and 13.4 6 3.9 d versus 12.7 6
3.3 d for amphotericin B, p ¼ 0.338, respectively, in HIV-
positive and -negative patients).
Two weeks after the diagnosis of cryptococcosis, outcomes
were available for 214 patients, of whom 14 died (Figure 1).
These early deaths (14/37 [38%] of all deaths) were recorded
in three HIV-negative and 11 HIV-positive patients, including
two without meningoencephalitis. They were more often
attributed to cryptococcosis than were deaths occurring later
(12/14 [86%] versus 7/23 [30%], p ¼ 0.002). Early deaths were
also more frequent among patients with abnormal neurology
(10/86 [12%] versus 4/128 [3%], p ¼ 0.021), abnormal brain
imaging (6/60 [12%] versus 2/125 [2%], p ¼ 0.007), abnormal
Table 2. Characteristics of Cryptococcosis that Significantly Differed between Sexes in 177 HIV-Infected Patients with Cryptococcosis
Category Parameter Male Patients (n ¼ 142) Female Patients (n ¼ 35) p-Value
Characteristics of all patients Fungaemia, % (positive/evaluated) 51 (69/135) 27 (9/33) 0.019
Positive urine culture, % (positive/evaluated) 35.5 (44/124) 10 (3/30) 0.007
Disseminated infection, % (positive/evaluated) 65.0 (89/137) 42.4 (14/33) 0.028
Meningoencephalitis, % (positive/evaluated) 90.8 (129/142) 82.3 (28/34) 0.213
Mean serum antigen titer, log2 6 SD 9.6 6 4.6 (127) 7.6 6 4.0 (31) 0.026
Median time interval between hospitalisation and
onset of antifungal therapy (IQR)
3.1 (1–4) 5.3 (1–8) 0.0535
CSF characteristics in patients
with meningoencephalitis
Median CSF cell count/ll (IQR) 12.5 (2–70) 22 (4–208) 0.245
Median CSF protein, g/l (IQR) 0.7 (0.4–1.2) 0.8 (0.6–14) 0.26
Mean CSF antigen titer, log2 6 SD 8.3 6 0.4 8.0 6 0.8 0.761
doi:10.1371/journal.pmed.0040021.t002
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Cryptococcosis in Adultsthoracic imaging (10/89 [11%] versus 4/119 [3%], p ¼ 0.047),
and hyponatraemia (12/115 [10%] versus 2/95 [2%], p¼0.023).
The presence of meningoencephalitis, HIV status, or sex did
not inﬂuence the proportions.
Of 200 patients (92%) that remained alive, 186 (93%) had
body ﬂuids sampled for culture (Figure 1). Among the
patients alive at Wk2, clinical cure was obtained in 115 of
200 patients (57.5%) with no difference according to HIV
status or sex. However, clinical cure was less frequently
recorded among patients with abnormal neurology (31/76
[41%] versus 84/124 [68%], p , 0.001) or meningoencephalitis
(90/168 [54%] versus 19/24 [78%], p ¼ 0.026) at baseline than
among others.
Control of sterilisation of the initially infected site was
performed for 150/178 [84%] of CSF, 53/79 [67%] of blood,
and 44/52 [85%] of urine samples. Among those considered
clinically cured, 29/105 [28%] still had one body site infected,
while among those who were considered clinical failures, 43/
81 [53%] were sterilised (p¼0.009). Encapsulated yeasts were
still seen in 97/148 [65%] of the CSF examined (87/128 [70%]
and 10/23 [43%] of the HIV-positive and -negative patients,
respectively, p¼0.030). CSF culture was still positive in 61/151
[40%] of the patients with initial meningoencephalitis, with
no difference according to HIV status. Overall, sterilisation
was not achieved in 67/186 [36%] of the patients after two
weeks of antifungal therapy.
Factors associated with mycological failure after two weeks
of antifungal therapy. We analysed, in the 186 patients
assessable at the Wk2 workup, the factors associated with
mycological failure whatever the initial presentation (pres-
ence or absence of meningoencephalitis) and the HIV status
(Table 4). In the absence of ﬂucytosine for induction therapy,
mycological failure was recorded in no solid organ transplant
recipients, 1/4 and 3/12 [25%] of seronegative patients with
no risk factor (group 4) or haematological malignancies
(group 2), respectively, and in 2/4 [50%] and 31/68 [54%] of
patients with miscellaneous risk factors (group 3) or HIV
infection, respectively (p¼0.075). In the multivariate analysis
(178 patients), presence of initial dissemination (OR, 2.4 [95%
CI, 1.2–4.9], p¼0.015), high serum antigen titer (OR, 2.6 [95%
CI, 1.3–5.4], p ¼ 0.008), and lack of ﬂucytosine during
induction therapy (OR, 3.8 [95% CI, 1.9–7.8], p , 0.001) were
independently associated with mycological failure at Wk2
(interaction terms among the three factors were not
signiﬁcant).
Factors associated with lack of CSF sterilisation in HIV-
positive patients with cryptococcal meningoencephalitis.
HIV-related parameters (CD4
þ cell count, viral load) had no
inﬂuence on the percentage of CSF sterilisation (Table 5).
The mean cumulative dose of ﬂucytosine (and the duration
but not the daily dosage, unpublished data) was lower in cases
of positive compared to negative CSF Wk2 cultures (mean
dose in grams 6 SD ¼ 69 6 49 versus 94 6 41, p ¼ 0.015),
whereas there was no difference in the mean cumulative dose
of ﬂuconazole or amphotericin B. In a multivariate analysis
involving 111 patients, an infection by serotype A (OR, 5.6
[95% CI, 1.6–19.8], p ¼ 0.008), a high CSF antigen titer at
baseline (OR, 14.1 [95% CI, 3.0–67.1], p ¼ 0.001) and the lack
of ﬂucytosine prescription during induction therapy (OR,
24.4 [95% CI, 4.8–123.5], p , 0.001) were independently
associated with lack of CSF sterilisation at Wk2 (interaction
terms among the three factors were not signiﬁcant).
Factors Associated with Death within Three Months of
Diagnosis of Cryptococcosis
At Mo3 (Figure 1), 177 patients remained alive, and
neurological sequelae were observed in seven HIV-positive
patients. Of the 177 survivors, 142 (80%) had a mycological
evaluation at Mo3. Three HIV-positive patients had still
viable yeasts in the CSF and one HIV-negative patient had a
positive bronchoalveolar lavage culture.
Overall, 37 patients (27 HIV-positive and ten HIV-negative)
died during follow-up in relation with cryptococcosis (19
patients, including four HIV-negative patients) or their
Table 3. Comparisons of Infections Due to C. neoformans Serotype A (var. grubii) and Serotype D (var. neoformans) According to HIV
Status
Patient Group Parameter Studied HIV-Positive Patients p-Value HIV-Negative Patients p-Value
Serotype A
(n ¼ 130)
Serotype D
(n ¼ 41)
Serotype A
(n ¼ 31)
Serotype D
(n ¼ 20)
All patients Mean age, years 6 SD 38.7 6 8.0 39.8 6 8.1 0.441 51.5 6 17.5 58.5 6 16.9 0.161
Born in Africa, % (evaluated) 35.7 (46/129) 17.1 (7/41) 0.033 16.1 (5/31) 0 (0/20) 0.143
Living in the Paris area, % (evaluated) 70.0 (91/130) 39.0 (16/41) 0.001 54.8 (17/31) 15.0 (3/20) 0.007
Smoking habit, % (evaluated) 54.2 65/(120) 69.2 (27/39) 0.135 43.3 (13/30) 63.2 (12/19) 0.244
Natraemia , 134 mEq/l, % (evaluated) 51.2 (66/129) 70.7 (29/41) 0.031 43.2 (13/30) 52.9 (9/17) 0.558
Mean serum antigen titer (log2) 6 SD 9.8 6 4.3 7.4 6 5.0 0.006 5.5 6 4.0 7.4 6 3.8 0.158
Disseminated infection, % (evaluated) 61.3 (76/124) 62.5 (25/40) 1 33.3 (10/30) 45.0 (9/20) 0.553
Meningoencephalitis, % (evaluated) 88.4 (114/129) 95.1 (39/41) 0.368 82.1 (23/28) 58.3 (7/12) 0.133
Patients with
meningoencephalitis
Median reciprocal CSF antigen titer (log2) 6 SD 8.6 6 4.0 7.2 6 4.6 0.104 4.7 6 4.4 10.8 6 3.3 0.002
CSF cell counts   20/ll, % (evaluated) 43.7 (63/112) 50.0 (19/38) 0.573 76.2 (6/21) 42.9 (4/7) 0.165
Abnormal brain imaging, % (evaluated) 30.8 (33/107) 32.4 (12/37) 0.84 28.6 (6/21) 0 (0/6) 0.284
Median interval between admission and antifungal
drug prescription, days (IQR)
1 (1–3) 2 (1–5) 0.055 4 (3–6) 14 (51–21) 0.055
Death at Mo3, % (evaluated) 15.0 (18/120) 17.5 (7/40) 0.802 17.9 (5/28) 27.8 (5/18) 0.48
Death attributed to cryptococcosis, % (deaths) 55.6 (10/18) 42.9 (3/7) 0.673 0 (0/5) 80.0 (4/5) 0.048
doi:10.1371/journal.pmed.0040021.t003
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patients). None of the seven HIV-negative immunocompetent
patients (group 4) died, including the three with meningoen-
cephalitis.
The survival probability at Mo3 was thus lower in patients
with abnormal neurology at baseline (survival probability 0.71
[95% CI, 0.60–0.80]) compared to those without (0.90 [95%
CI, 0.84–0.94], p ¼ 0.0008), in patients with haematological
malignancies (0.54 [95% CI, 0.29–0.74]) compared to those
without (0.85 [95% CI, 0.79–0.90], p ¼ 0.011), and in patients
with abnormal brain imaging at baseline (0.74 [95% CI, 0.53–
0.83]) compared to those with normal brain imaging (0.88
[95% CI, 0.81–0.93], p ¼ 0.0274) (Figure 2). Abnormal
neurology and abnormal brain imaging still inﬂuenced
survival probability when patients with concomitant or past
cerebral toxoplasmosis were excluded (unpublished data).
Discussion
We analysed in a prospective study the determinants of
clinical presentation and outcome in patients with incident
cryptococcosis in France, 1997–2001. Based on this popula-
tion, cryptococcosis was more severe in men, in HIV-positive
patients, and patients infected with serotype A C. neoformans.
Factors independently associated with mycological failure at
Wk2, regardless of the HIV status, were: initial dissemination,
high serum antigen titer at baseline, and lack of ﬂucytosine
during induction therapy. The Mo3 survival was lower in
Table 4. Parameters Associated with Mycological Failure at the Wk2 Workup in 186 HIV-Positive and -Negative patients with
Cryptococcosis (All Cases): Univariate and Multivariate Analyses
Stage Parameter Univariate Analysis Multivariate Analysis
Mycological
Cure, % (n)
Mycological
Failure, % (n)
p-Value OR
(95% CI)
p-Value
Parameters at baseline Male sex
a 74.8 (89/119) 89.5 (60/67) 0.021
Abnormal neurology 35.3 (42/119) 47.8 (32/67) 0.119
Disseminated infection
a 46.2 (55/119) 71.6 (48/67) 0.001 2.4 (1.2–4.9) 0.015
Meningoencephalitis 82.6 (95/115) 95.5 (64/67) 0.011
Fungaemia 33.0 (39/118) 51.6 (33/64) 0.018
Positive urine culture 23.2 (26/112) 39.3 (24/61) 0.025
Serotype A isolate
a 71.0 (81/114) 80.0 (52/65) 0.216
High (  1:512) serum antigen titer
a 36.0 (41/116) 56.2 (36/64) 0.012 2.6 (1.3–5.4) 0.008
High (  1:512) CSF antigen titer 32.0 (33/103) 60.3 (35/58) 0.001
Positive India ink test 66.1 (76/115) 83.3 (55/66) 0.015
Lack of flucytosine for induction therapy
a 41.2 (49/112) 64.2 (43/67) 0.004 3.8 (1.9–7.8) ,0.001
Parameters at the Wk2 workup Neurological defect 1.8 (2/113) 19.3 (12/62) ,0.001
Positive India ink test 48.4 (45/93) 86.4 (51/59) ,0.001
Clinical cure 63.9 (76/119) 43.3 (29/67) 0.009
aInitially entered into the logistic regression model.
doi:10.1371/journal.pmed.0040021.t004
Table 5. Parameters Associated with Lack of CSF Sterilisation in 127 HIV-Positive Patients with Cryptococcal Meningoencephalitis:
Univariate and Multivariate Analyses
Stage Parameter Univariate Analysis Multivariate Analysis
CSF Sterilisation Lack of CSF Sterilization p-Value OR (95% CI) p-Value
Parameters at baseline Male sex
a 78.4 (58/74) 86.8 (46/53) 0.252
Abnormal neurology 44.6 (33/74) 51.0 (27/53) 0.589
Disseminated infection
a 54.0 (40/74) 75.5 (40/53) 0.016
Fungaemia 41.1 (30/73) 62.0 (31/50) 0.028
Positive urine culture 21.7 (15/69) 42.6 (20/47) 0.023
Serotype A isolate
a 64.8 (46/71) 86.5 (45/52) 0.007 5.6 (1.6–19.8) 0.008
High (  1:512) serum antigen titer 44.3 (31/70) 64.0 (32/50) 0.042
High (  1:512) CSF antigen titer
a 44.1 (30/68) 69.6 (32/46) 0.012 14.1 (2.9–67.1) 0.001
Positive India ink test 87.8 (65/74) 92.3 (48/52) 0.556
Lack of flucytosine for
induction therapy
32.4 (24/74) 60.4 (32/53) 0.002 24.4 (4.8–123.5) ,0.001
Parameters at the Wk2 workup Neurological defect
a 4.3 (3/70) 16.7 (8/48) 0.048
Positive India ink test 55.4 (41/74) 90.2 (46/51) ,0.001
Clinical cure 56.8 (42/75) 43.4 (23/53) 0.153
aInitially entered into the logistic regression model
doi:10.1371/journal.pmed.0040021.t005
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Cryptococcosis in AdultsFigure 2. Overall Survival at Three Months after the Diagnosis of Cryptococcosis
(A) Patients presenting with and without abnormal neurology at baseline.
(B) Patients with and without haematological malignancies.
(C) Patients presenting with and without abnormal brain imaging at baseline (data missing for 39 patients).
doi:10.1371/journal.pmed.0040021.g002
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at baseline, and in those with haematological malignancy.
As this was an observational study, there are limitations to
the data available for analysis despite a low rate of patients
lost to follow-up. Principal among these limitations is the
potential for selection of the patients. Although we veriﬁed
that patients enrolled in the CryptoA/D study and those
notiﬁed through the nationwide epidemiological survey did
not differ according to type of underling disease, sex, and
cryptococcosis presentation (especially the proportion of
extrameningeal infection), other patients could have been left
out of both studies. Our study reﬂects the situation in a
European country where serotypes A and D are present in the
environment. Other data could be obtained in a different
environment especially in countries where C. gattii exists.
Handling of the biological samples was not centralised, which
could introduce variations in the yield of positive cultures
due to variation in laboratory practices. Finally, the question
of multiple comparisons adjustment is a subject of debate in
epidemiological research [30,34], arising because of the
increased risk of type I errors (ﬁndings of false signiﬁcance)
when numerous hypotheses are tested simultaneously at set p-
values. We thus limited the adjustment to the main outcomes
and engaged other comparisons to present exploratory but
relevant results [35].
CSF cultures were more frequently positive for C. neofor-
mans in HIV-positive than in HIV-negative patients [2,31].
There was more pronounced cryptococcosis-associated CSF
inﬂammation in HIV-negative patients than in HIV-positive
patients. This corroborates previous studies comparing
inﬂammatory cytokine and mediator levels in CSF during
cryptococcosis in humans [36] or demonstrating the role of
inﬂammatory cytokines during cryptococcosis [37–39]. Fun-
gaemia is probably a critical step in the development and
persistence of meningoencephalitis [40] as further evidenced
by a higher percentage of fungaemia paralleling the higher
percentage of meningoencephalitis at baseline and of CSF
nonsterilisation at Wk2 in HIV-positive patients. It even
suggests that C. neoformans persistently circulating in blood
may contribute to subsequent reinfection of the central
nervous system, an hypothesis supported by data obtained in
the early stage of infection in a mouse model of disseminated
cryptococcosis [41].
We found a signiﬁcant difference in the proportion of
males and females in HIV-positive and -negative patients with
cryptococcosis (the male:female ratio among patients with
AIDS in France was then 2.8:1 [42]). In addition, there was a
sex difference in terms of disease characteristics at baseline.
A higher production of inﬂammatory cytokines was measured
in female versus male mice associated with a nonsigniﬁcant
trend toward a lower fungal burden in females [43]. Overall,
these data suggest the inﬂuence of sex hormones—possibly
through inﬂammatory mediators—in the control of crypto-
coccosis and not only in the susceptibility to infection.
In clinical practice, cryptococcal antigen detection and
titration are used to evaluate dissemination, severity of
disease, and response to treatment. Negative antigen detec-
tion in serum does not rule out dissemination even in HIV-
negative patients (three cases in this study). Likewise, negative
antigen detection in CSF, although rare, is not incompatible
with true meningoencephalitis [21]. We showed that antigen
titres were signiﬁcantly higher in all situations associated with
evidence of dissemination. High CSF antigen titres have been
associated with lack of CSF sterilisation [44,45] or death
[22,44,46] in HIV-positive patients with meningoencephalitis.
An association between high serum antigen titres and early
outcome has not been demonstrated in HIV-negative patients
or extrameningeal cryptococcosis since a study published
with the ﬁrst agglutination test [28]. A threshold of 1:512 or
higher should thus help monitor patients with cryptococcosis
whatever their HIV status. A serum antigen titer 1:512 or
higher during follow-up was also identiﬁed as an independent
factor of cryptococcosis relapse in a study of the long-term
outcome of cryptococcosis in patients with AIDS [47].
TheWk2workupisnowconsidered amajormilestoneinthe
management of cryptococcal meningitis. Indeed, the recom-
mended treatment is a combination of amphotericin B (0.7
mg/kg/d) and ﬂucytosine (100 mg/kg/d) for two weeks, followed
by ﬂuconazole at a dosage of 400 mg/d or higher for ten weeks
[18,22,24]. Flucytosine prescription has been associated with
toxicity [19,24,48], but lower dosages and monitoring of
plasma drug levels can prevent this problem. Combination
therapy is associated with lower rates of subsequent relapse
during maintenance therapy [23] and sterilisation of CSF as
determined by culture [19]. Recent data obtained in HIV-
positive patients in Thailand showed also that clearance of
cryptococci from the CSF was signiﬁcantly faster with
amphotericin B–ﬂucytosine compared to amphotericin B
alone or other combination therapies [49]. Here, the lack of
ﬂucytosine—and not only the lack of combination therapy
with amphotericin B and ﬂucytosine—during the induction
phase was independently associated with lack of CSF
sterilisation (HIV-positive patients) or mycological failure
(entire population) at Wk2. We showed in vitro and in a
murine model of cryptococcosis that synergy can be achieved
with amphotericin B–ﬂucytosine combination therapy even if
the isolate is resistant to ﬂucytosine in vitro [50–52]. Thus,
together with data previously published in HIV-positive
patients showing that early mycological failure can be
associatedwithdeath[45],ourresultssupporttheprescription
of ﬂucytosine for induction treatment of cryptococcosis in all
situations in which a high fungal burden is suspected based on
antigen titration or cultures, regardless of HIV status.
We observed an overall mortality rate in patients with
cryptococcosis of 6.5% in the ﬁrst two weeks and 11.5% in
the next ten weeks, comparable to other reports [22,45] but
higher than the most recent randomized trial of the Mycoses
Study Group [24]. The higher mortality rate observed in our
study can be explained by a high proportion of severe cases as
well as by the lack of systematic management of intracranial
pressure in France. High intracranial pressure has been
associated with poor prognosis [44], and failure to control it
has been linked to neurological injuries [53]. Factors
predictive of deaths within three months after the diagnosis
were underlying haematological malignancy, presence at
baseline of abnormal neurology, or abnormal brain imaging.
Despite the apparent contraction, survival was reported
lower in HIV-negative compared to HIV-positive patients
even before the introduction of HAART [54], and the
mortality rate was even higher in HIV-negative patients with
haematological malignancies [20,21]. Abnormal neurology
has already been associated with a poor prognosis in several
studies [28,29]. Abnormal brain imaging at baseline was
uncovered here as a parameter associated with death from
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phies or magnetic resonance imaging of the brain have been
published so far, and none has clearly addressed the
relationship between cerebral lesions and prognosis [1]. Thus,
brain lesions speciﬁcally associated with a poor prognosis are
currently being analysed on a subset of patients with
meningoencephalitis based on blinded review of the brain
images.
Finally, despite data indicating that serotypes A and D
differ in terms of host infected, clinical presentation, and
even early outcome, differences are far less striking than
those reported between C. neoformans and C. gattii [15–17],
thus supporting the current concept of two varieties of the
same species rather than two species [55]. Despite additional
differences between serotypes A and D in terms of suscept-
ibility to amphotericin B and ﬂuconazole but not ﬂucytosine,
the similar long-term outcome may be explained by the lack
of correlation between in vitro and in vivo results [56] or
other still uncovered factors.
Despite the decline in the incidence of cryptococcosis,
mortality rate remains about 15%–20% at Mo3 in HIV-
negative and HIV-positive patients in countries where
HAART is available [47] and much higher in some countries
of Africa and Southeast Asia [5,57,58], thus calling for
improvement of therapeutic management. Patients who
should beneﬁt from a two-week induction therapy with
amphotericin B and ﬂucytosine are those with meningoence-
phalitis or severe pneumonia, regardless of HIV status, as
already proposed in the Infectious Diseases Society of
America guidelines [18]. We suggest adding to the current
recommendations patients with high fungal burden regard-
less of HIV status, i.e., those with serum antigen titer 1:512 or
higher, or those with fungaemia or disseminated infection
(deﬁned by two noncontiguous infected body sites including
urine). Our current analysis does not allow us to alter the
recommendations concerning the induction therapy for
other clinical presentations (400 mg/d of ﬂuconazole) or for
the consolidation phase (ﬂuconazole 400 mg/d for ten weeks).
We strongly advocate, however, that evidence of cryptococ-
cosis—based on positive antigen detection and/or presence of
encapsulated yeasts at direct examination/histology and/or
isolation of C. neoformans from any body site—be immediately
followed by sampling and culture of CSF, blood, and urine,
and by serum antigen titration in order to evaluate fungal
burden and optimize induction treatment.
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Editors’ Summary
Background. For people with a healthy immune system, athletes’ foot
may be the only fungal infection they ever have. But individuals whose
immune system has been damaged by infection with HIV or who are
immune-suppressed after organ transplantation or cancer chemotherapy
can develop cryptococcosis. This is a life-threatening infection caused by
Cryptococcus neoformans, a fungus found in bird droppings that enters
the human body through the lungs. The initial infection can go
unnoticed, although a pneumonia-like disease sometimes develops.
However, if the fungus spreads (disseminates) around the body it can
cause other symptoms. The commonest of these is cryptococcal
meningitis, a swelling of the membrane around the brain that can
cause a stiff neck, headaches, and neurological symptoms such as
palsies. For anyone with cryptococcal meningitis or severe pneumonia
the current treatment guidelines recommend a two-week induction
therapy with the antifungal drugs amphotericin B and flucytosine,
followed by fluconazole for ten weeks.
Why Was This Study Done? Even when these guidelines are followed,
cryptococcosis kills some people. The guidelines are based on data from
clinical trials of antifungal drugs in HIV-positive patients done before
there were effective treatments for HIV infections. Patients without
meningitis and those with very severe disease were excluded from these
trials. Also, it is known that two variants of C. neoformans cause
cryptococcosis: variety grubii (also known as serotype A) and variety
neoformans (serotype D). There is very little information about the
impact of patient-related factors (such as sex, age, and HIV status) or the
variety of C. neoformans on clinical presentation (the symptoms patients
have when they first visit a doctor), therapeutic management, or disease
outcomes in the real world; this information is needed to improve the
treatment guidelines. In this nationwide study across France, the
researchers have asked what factors influence clinical presentation and
outcomes in HIV-positive and HIV-negative patients with cryptococcosis,
and whether infections with the two varieties of C. neoformans behave
similarly.
What Did the Researchers Do and Find? Patients were enrolled in the
study when their first episode of cryptococcosis was confirmed by
growing C. neoformans from blood, urine, or cerebrospinal fluid.
Information was collected about their initial symptoms, which body
sites were infected with fungus (their mycological status), and their
treatment. Clinical and mycological data were also collected at two
weeks and three months, and the blood levels of cryptococcal secreted
molecules were measured to provide a ‘‘serum antigen titer,’’ a measure
of fungal load. The researchers found that cryptococcosis was more
severe at presentation in men, in HIV-positive patients, and in patients
infected with C. neoformans variety grubii. Patients whose treatment
failed at two weeks (judged by the continued presence of C. neoformans
in culture of their body fluids) tended to have disseminated disease at
presentation, to have high serum antigen titers, and not to have been
given flucytosine during the initial round of therapy. Finally, three-month
survival was worse in patients with abnormal neurology or brain imaging
at the start of the study, or those with hematological malignancies
(cancers that affect immune system cells).
What Do These Findings Mean? These findings provide new
information on what determines the clinical presentation and outcome
in patients with cryptococcosis. Because the study was done in France,
these results will only apply to other countries where C. neoformans
causes cryptococcosis—in some countries C. gattii can cause the disease.
In addition, not all of the cryptococcosis cases that occurred in France
during the study period were enrolled in the study, so it is possible that
the infection might have had different characteristics in the missing
patients. Nevertheless, the results of this study suggest that more
patients would benefit from a two-week induction therapy with
amphotericin B and flucytosine than currently recommended. This
treatment, write the researchers, should be given to all patients with a
high serum antigen titer, fungus in the blood, or initial infection at two
separate body sites (in addition to those with cryptococcal meningitis or
severe pneumonia for whom it is currently recommended). They also
suggest that the fungal burden should be routinely determined in all
patients so that their treatment can be adjusted if necessary.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040021
  A related PLoS Medicine Perspective article discusses current manage-
ment of cryptococcosis
  MedlinePlus has encyclopedia pages on cryptococcosis
  US Centers for Disease Control and Prevention provides information
on cryptococcosis
  Aidsmap has information on cryptococcosis and research into the
disease provided by the charity NAM
  A Clinical Infectious Diseases article published in 2000 states the
current treatment guidelines for the management of cryptococcosis
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